Haynes DR - Search Results

1

Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone.

Atkins GJ, Bouralexis S, Haynes DR, Graves SE, Geary SM, Evdokiou A, Zannettino AC, Hay S, Findlay DM. Atkins GJ, et al. Among authors: haynes dr. Bone. 2001 Apr;28(4):370-7. doi: 10.1016/s8756-3282(01)00404-5. Bone. 2001. PMID: 11336917

2

Pro-inflammatory cytokines TNF-related weak inducer of apoptosis (TWEAK) and TNFalpha induce the mitogen-activated protein kinase (MAPK)-dependent expression of sclerostin in human osteoblasts.

Vincent C, Findlay DM, Welldon KJ, Wijenayaka AR, Zheng TS, Haynes DR, Fazzalari NL, Evdokiou A, Atkins GJ. Vincent C, et al. Among authors: haynes dr. J Bone Miner Res. 2009 Aug;24(8):1434-49. doi: 10.1359/jbmr.090305. J Bone Miner Res. 2009. PMID: 19292615 Free article.

3

Regulation of bone cells by particle-activated mononuclear phagocytes.

Haynes DR, Hay SJ, Rogers SD, Ohta S, Howie DW, Graves SE. Haynes DR, et al. J Bone Joint Surg Br. 1997 Nov;79(6):988-94. doi: 10.1302/0301-620x.79b6.7832. J Bone Joint Surg Br. 1997. PMID: 9393919

4

Bidirectional signaling between stromal and hemopoietic cells regulates interleukin-1 expression during human osteoclast formation.

Haynes DR, Atkins GJ, Loric M, Crotti TN, Geary SM, Findlay DM. Haynes DR, et al. Bone. 1999 Sep;25(3):269-78. doi: 10.1016/s8756-3282(99)00176-3. Bone. 1999. PMID: 10495130

5

Expression of osteoclast differentiation signals by stromal elements of giant cell tumors.

Atkins GJ, Haynes DR, Graves SE, Evdokiou A, Hay S, Bouralexis S, Findlay DM. Atkins GJ, et al. Among authors: haynes dr. J Bone Miner Res. 2000 Apr;15(4):640-9. doi: 10.1359/jbmr.2000.15.4.640. J Bone Miner Res. 2000. PMID: 10780856 Free article.

6

Coordinated cytokine expression by stromal and hematopoietic cells during human osteoclast formation.

Atkins GJ, Haynes DR, Geary SM, Loric M, Crotti TN, Findlay DM. Atkins GJ, et al. Among authors: haynes dr. Bone. 2000 Jun;26(6):653-61. doi: 10.1016/s8756-3282(00)00280-5. Bone. 2000. PMID: 10831938

7

Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint.

Haynes DR, Crotti TN, Loric M, Bain GI, Atkins GJ, Findlay DM. Haynes DR, et al. Rheumatology (Oxford). 2001 Jun;40(6):623-30. doi: 10.1093/rheumatology/40.6.623. Rheumatology (Oxford). 2001. PMID: 11426018

8

The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis.

Haynes DR, Crotti TN, Potter AE, Loric M, Atkins GJ, Howie DW, Findlay DM. Haynes DR, et al. J Bone Joint Surg Br. 2001 Aug;83(6):902-11. doi: 10.1302/0301-620x.83b6.10905. J Bone Joint Surg Br. 2001. PMID: 11521937 Review.

9

Human osteoblasts are resistant to Apo2L/TRAIL-mediated apoptosis.

Atkins GJ, Bouralexis S, Evdokiou A, Hay S, Labrinidis A, Zannettino AC, Haynes DR, Findlay DM. Atkins GJ, et al. Among authors: haynes dr. Bone. 2002 Oct;31(4):448-56. doi: 10.1016/s8756-3282(02)00858-x. Bone. 2002. PMID: 12398939

10

Factors regulating osteoclast formation in human tissues adjacent to peri-implant bone loss: expression of receptor activator NFkappaB, RANK ligand and osteoprotegerin.

Crotti TN, Smith MD, Findlay DM, Zreiqat H, Ahern MJ, Weedon H, Hatzinikolous G, Capone M, Holding C, Haynes DR. Crotti TN, et al. Among authors: haynes dr. Biomaterials. 2004 Feb;25(4):565-73. doi: 10.1016/s0142-9612(03)00556-8. Biomaterials. 2004. PMID: 14607494 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

147 results

Search Page